Company
Not a product brand. A platform company.
For over 12 years, Jowin Inc. has combined prevention products with medical validation, hospital networks, insurance linkage, and patent protection — so prevention can finally operate as a trusted, sustainable category.
What we are
Preventive healthcare
Jowin connects prevention products, medical professionals, validation systems, and insurance structures into a single licensable model.
The point is not to sell better supplements. It is to change how the prevention market works — by making products verifiable, tying them to insurance coverage, and handing country partners a complete, ready-to-localize system.
What we are not
Global licensing
We are not a brand competing on packaging and ad spend. We are not a single-product company. We do not ship containers of supplements.
We license the model — patents, formulas, ingredient supply, insurance-linked structure, and brand rights — to one partner per country, to operate locally.
Corporate basics
Jowin Inc.
Patent: HealthInsu™ business-model registration · Headquartered in the Republic of Korea
Validated in Korea
Validated by the numbers
Why Jowin
Six things in your hands on day one of licensing.
Prevention R&D
Disease-specific prevention formulas, key ingredient supply chains, and clinical-grade validation logic — assets built up over more than a decade.
Patent protection
The HealthInsu™ model is protected by business-model and system patents, layered to defend across multiple jurisdictions.
Validated in market
Valued at approximately USD 930 million by Hyundai Accounting. First disease-specific prevention launch sold through. Local-government discussions underway.
Hospitals + insurers + manufacturers
Specialty hospitals, supplement manufacturers, insurers, and marketing partners — already wired into the same model.
HiClinic specialty companies
HiEyes, HiDental, HiJoint — independent verticals built alongside specialist physicians, each with its own growth path.
Platform trajectory
Near term: country-level licensing and public listing. Long term: an own-platform play in global preventive insurance.
Korean reference points
The basis behind the valuation.
≈ USD 930 million
Independent valuation of the HealthInsu™ model by Hyundai Accounting Corporation.
First prevention launch sold through
Jowin's first disease-specific prevention product sold through after launch — an early demand signal in a validated prevention category.
Seoul eye-clinic collaboration
Specialty eye clinics in Seoul have introduced eye-health supplements connected to the HealthInsu™ model.
Local-government adoption talks
Korean local governments are reviewing the HealthInsu™ system for senior healthcare programs.
Hyundai Marine & Fire
Active partnership discussions to develop prevention-linked insurance products.
Layered patent portfolio
Multi-layer business-model and system patents in Korea, with additional and global filings in progress.
Roadmap
From Korean validation to a global platform — in six stages.
-
Stage 1 · Consolidate
Stabilize the Korean model
Activate Jowin's own channels, structure the domestic licensing pipeline, validate HiClinic verticals, stabilize the trial program.
-
Stage 2 · Expand
License into 10 countries
Identify, qualify, and contract country-level partners in 10 priority markets — each operating a fully localized HealthInsu™ business.
-
Stage 3 · IPO
Jowin public listing
With 10-country traction as the basis, Jowin pursues a public listing. Indicative target enterprise value at IPO: approximately USD 1 billion.
-
Stage 4 · Verticals
HiClinic specialty companies
HiEyes, HiDental, HiJoint, women's-health verticals, oncology — each spun out as an independent specialty company on its own growth and listing path.
-
Stage 5 · Platform
Global prevention-insurance platform
From insurer partnerships to an own-platform play in global preventive insurance — the long-horizon objective beyond licensing.
-
Stage 6 · Scale
100+ countries
From 10 priority markets to a global footprint, supported by regional sub-licensing structures.
Forward-looking statements describe internal targets and structural intent, not guarantees. All long-term licensing, valuation, and IPO terms are subject to separate agreement and regulatory review.